藤黄健骨胶囊结合西医治疗膝关节骨性关节炎有效性和安全性的Meta分析-现代医学

藤黄健骨胶囊结合西医治疗膝关节骨性关节炎有效性和安全性的Meta分析

单位：昆明医科大学第六附属医院骨科, 云南玉溪 653100

分类号：R684.3

出版年·卷·期（页码）：2023·51·第五期（598-603）

摘要：

目的：系统评价藤黄健骨胶囊结合西医治疗膝关节骨性关节炎(KOA)的有效性和安全性。方法：应用Embase、PubMed、Cochrane Library、万方(WanFang)、中国知网(CNKI)、中国生物医学文献库(CBM)等数据库检索有关藤黄健骨胶囊结合西医治疗KOA的文献，严格按照纳排标准筛选出所需文献，使用Cochrane 5.1.0偏倚风险评估标准对文献进行评价，应用RevMan 5.4软件进行数据分析。结果：共纳入随机对照研究14项，涉及KOA患者1 531例。Meta分析结果显示藤黄健骨胶囊结合西医治疗KOA优于单纯西医治疗，其中有效率(OR＝3.97，95%CI为2.50～6.30，P＜0.05)、VAS评分(WMD=-1.06，95%CI为-1.37～-0.75)，P＜0.05)、Lysholm评分(WMD＝11.35，95%CI为7.39～15.32，P＜0.05)、白细胞介素-1β(IL-1β)水平(WMD=-13.32，95%CI为-21.70～-4.95，P＜0.05)差异有统计学意义，而两组不良反应发生率差异无统计学意义(OR＝0.81，95%CI为0.51～1.31)，P＜0.40)。结论：藤黄健骨胶囊结合西医治疗KOA的疗效优于单纯西医治疗，但此结论尚待更多大样本、高质量的随机对照研究进行论证。

Objective: To evaluate the efficacy and safety of Tenghuang Jiangu capsule combined with Western medicine in the treatment of knee osteoarthritis(KOA). Methods: The Embase, PubMed, Cochrane Library, WanFang, CNKI, CBM were searched for the literatures on the treatment of osteoarthritis with Tenghuang Jiangu capsule combined with Western medicine, and the required literatures were screened out strictly according to the inclusion and exclusion criteria. Cochrane 5.1.0 bias risk assessment criteria was used to evaluate the literature, and RevMan 5.4 software was employed for data analysis. Results: A total of 14 literatures were included, involving 1 531 patients with KOA.The results of Meta-analysis showed that the combination of Tenghuang Jiangu capsule and Western medicine in the treatment of osteoarthritis was better than that of western medicine alone, with an effective rate of(OR=3.97， 95%CI 2.50-6.30，P＜0.05), VAS score of(WMD=-1.06， 95%CI-1.37--0.75)，P＜0.05), Lysholm score of(WMD=11.35，95%CI 7.39-15.32，P＜0.05) and IL-1β level of(WMD=-13.32，95%CI-21.70--4.95，P＜0.05), the difference being statistically significant(P＜0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(OR=0.81，95%CI 0.51-1.31，P＜0.40). Conclusion: The efficacy of Tenghuang Jiangu capsule combined with Western medicine in the treatment of osteoarthritis is better than that of Western medicine alone. Large sample and high quality randomized controlled trials are needed to confirm the results.

参考文献：

[1] HUSSAIN S M,NEILLY D W,BALIGA S,et al.Knee osteoarthritis:a review of management options[J].Scott Med J,2016,61(1):7-16.
[2] 彭文忠,刘渝松,张文斌.中西医治疗膝关节骨性关节炎研究进展[J].中国药业,2022,31(19):124-127.
[3] MAHMOUDIAN A,LOHMANDER L S,MOBASHERI A,et al.Early-stage symptomatic osteoarthritis of the knee-time for action[J].Nat Rev Rheumatol,2021,17(10):621-632.
[4] 徐振华,袁付成,岳春彦.藤黄健骨胶囊治疗膝骨关节炎临床研究[J].新中医,2022,54(16):108-111.
[5] 谌泽芳,邓天好,刘珍,等.中药对原发性肝癌复发转移临床疗效的Meta分析[J].中医肿瘤学杂志,2022,4(6):66-74.
[6] 张波,卢敏,唐盾.藤黄健骨片、玻璃酸钠联用与单用玻璃酸钠治疗骨性关节炎疗效比较[J].中国当代医药,2010,17(17):67-68.
[7] 钟彩玲,高利霞,陈艳,等.藤黄健骨片联合玻璃酸钠注射液治疗膝骨关节炎的效果[J].中国中医药现代远程教育,2016,14(12):109-110.
[8] 王自耿,阴小龙.藤黄健骨丸联合关节镜手术治疗膝骨性关节炎疗效分析[J].中医药临床杂志,2018,30(4):732-735.
[9] 吕根兵.潮式关节腔冲洗、玻璃酸钠关节内注射联合藤黄健骨片治疗积液型膝关节骨性关节炎疗效观察[J].现代中西医结合杂志,2018,27(25):2794-2796.
[10] 李智豪,贾晓鹏.藤黄健骨胶囊联合常规疗法治疗骨性关节炎疗效观察[J].新中医,2018,50(11):116-118.
[11] 李西要.藤黄健骨丸联合洛索洛芬钠治疗膝骨关节炎的临床研究[J].现代药物与临床,2019,34(1):169-172.
[12] 张赓栋,陈志坚,翁奇林.藤黄健骨丸联合关节镜手术治疗膝骨关节炎临床研究[J].新中医,2020,52(10):71-73.
[13] 司文腾,陈宾,周宇.藤黄健骨胶囊联合玻璃酸钠治疗膝骨关节炎的临床研究[J].现代药物与临床,2020,35(3):525-528.
[14] 刘军,卢靖雯.藤黄健骨胶囊治疗膝骨关节炎合并骨质疏松症临床分析[J].辽宁中医杂志,2020,47(6):105-107.
[15] 郭春何.藤黄健骨胶囊联合盐酸氨基葡萄糖胶囊治疗骨关节炎临床观察[J].糖尿病天地,2020,17(11):82-84.
[16] 何浩,于凯,刘海燕,等.藤黄健骨胶囊联合艾瑞昔布治疗膝骨关节炎的临床研究[J].现代药物与临床,2021,36(10):2107-2110.
[17] 张磊,陈皇珍,马爱军,等.膝关节腔内注射玻璃酸钠联用藤黄健骨胶囊治疗膝骨关节炎疗效及对炎症相关因子的影响[J].现代中西医结合杂志,2021,30(7):730-733,787.
[18] 张康.藤黄健骨胶囊联合塞来昔布胶囊治疗膝骨关节炎的临床研究[J].辽宁中医杂志,2022,49(1):95-98.
[19] 刘兆丰,王大斌,李军.藤黄健骨片联合常规西药对老年膝关节骨性关节炎(肝肾不足、筋脉瘀滞证)的作用[J].中国老年学杂志,2022,42(6):1424-1427.
[20] KIM J R,YOO J J,KIM H A.Therapeutics in osteoarthritis based on an understanding of its molecular pathogenesis[J].Int J Mol Sci,2018,19(3):674.
[21] 王迷娜,刘璐,赵洛鹏,等.膝骨关节炎炎性因子及信号通路的研究进展[J].中国骨伤,2020,33(4):388-392.
[22] KAPOOR M,MARTEL-PELLETIER J,LAJEUNESSE D,et al.Role of proinflammatory cytokines in the pathophysiology of osteoarthritis[J].Nat Rev Rheumatol,2011,7(1):33-42.
[23] ZENG G Q,CHEN A B,LI W,et al.High MMP-1,MMP-2,and MMP-9 protein levels in osteoarthritis[J].Genet Mol Res,2015,14(4):14811-14822.
[24] 付智慧,张晓川,周霖,等.基于网络药理学探讨藤黄健骨胶囊治疗骨性关节炎的作用机制研究[J].现代药物与临床,2021,36(8):1567-1576.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录